Drug Research and Drug Development in the 21st Century Science and Ethics /
Autor Corporativo: | |
---|---|
Otros Autores: | , , |
Formato: | eBook |
Lenguaje: | English |
Publicado: |
Berlin, Heidelberg :
Springer Berlin Heidelberg : Imprint: Springer,
1989.
|
Edición: | 1st ed. 1989. |
Colección: | Bayer AG Centenary Symposium,
|
Materias: | |
Acceso en línea: | https://doi.org/10.1007/978-3-642-74615-4 |
Tabla de Contenidos:
- History and Philosophy of Bayer Pharmaceutical Research
- Science, Responsibility, and Society
- Opening Remarks
- Message of Greeting
- I. Unresolved Problems of Chronic Diseases
- Demographic and Epidemiologic Trends Today
- Atherosclerosis and Coronary Heart Disease
- Rheumatoid Arthritis: A Modell of Chronic Inflammation
- Alzheimer’s Disease
- Obstructive Lung Disease
- Biological Approaches to Cancer Therapy
- Challenges and Obstacles hi Clinical Evaluations of Therapy
- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials
- The Impact of Clinical Trials on Clinical Practice
- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics
- II. Advanced Technologies, Scientific Achievements
- Receptors and Messengers
- Low Density Lipoproteins and Hypercholesterolemia
- Leukotrienes in Airways and Blood Vessels
- Drug Design
- Opening Remarks
- Thoughts About Gene Regulation and Mammalian Development
- Protein Crystallography and Drug Design
- Applying Engineering Principles to the Design of Cellular Biology
- Analytical Pathophysiology and Biochemistry
- Opening Remarks
- Neurotransmitters in the Brain
- Mechanisms of Cancer Metastasis
- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing
- The Patient as a Subject to Medical Research
- Ethics of Drug Research and Drug Development
- The Functions of Ethical Committees
- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development
- The Quality of Life of Hypertensive Patients in Long-term Studies
- Panel Discussion III: Who is Concerned with Patient Welfare in Research?
- Concluding Remarks.